Cencora, Inc. (NYSE:COR) Shares Bought by Leith Wheeler Investment Counsel Ltd.

Leith Wheeler Investment Counsel Ltd. boosted its position in Cencora, Inc. (NYSE:COR - Free Report) by 5.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 82,952 shares of the company's stock after acquiring an additional 4,126 shares during the period. Cencora accounts for approximately 1.3% of Leith Wheeler Investment Counsel Ltd.'s portfolio, making the stock its 17th largest holding. Leith Wheeler Investment Counsel Ltd.'s holdings in Cencora were worth $18,638,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Norges Bank bought a new position in shares of Cencora in the fourth quarter worth approximately $478,309,000. Raymond James Financial Inc. bought a new stake in shares of Cencora during the 4th quarter worth $322,460,000. Invesco Ltd. increased its position in shares of Cencora by 20.4% during the 4th quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock valued at $728,757,000 after purchasing an additional 550,246 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Cencora by 67.7% during the fourth quarter. The Manufacturers Life Insurance Company now owns 844,179 shares of the company's stock valued at $189,670,000 after purchasing an additional 340,862 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Cencora by 140.6% in the fourth quarter. Renaissance Technologies LLC now owns 550,700 shares of the company's stock valued at $123,731,000 after acquiring an additional 321,800 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. This represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. This trade represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,223 shares of company stock valued at $13,580,967 in the last three months. Corporate insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on COR shares. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. UBS Group lifted their price target on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Evercore ISI boosted their price target on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Finally, Bank of America boosted their target price on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $290.00.

Cencora Stock Performance

COR traded up $1.74 during midday trading on Friday, hitting $292.17. 1,046,574 shares of the company traded hands, compared to its average volume of 1,511,470. The company's 50-day moving average is $271.82 and its 200 day moving average is $251.02. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm has a market capitalization of $56.66 billion, a PE ratio of 41.56, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $296.65.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.